Suven Life Sciences
SUVEN · Pharma > Pharmaceuticals & Drugs · Chairman: Venkateswarlu Jasti Listing date: Oct. 23, 2003 · Employees: 130 · Hyderabad · http://www.suven.com

Stock Price vs Company Growth
1d
0.9%
1w
4.5%
1m
3.8%
3m
4.3%
6m
24.9%
1y
10.1%
5y
15.3%
10y
5.2%
all
8.0%
Created with Highcharts 8.2.2SalesProfitPriceDividendQtr SalesOperating CashflowDec10Jun14Dec17Jun21Latest

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

116 0.9%
106
167
Company Overview

Sales
7.57 Cr
Growth: -0.6%
Profit after Tax
-143 Cr
Growth: -1.8%
Small Cap
2,541 Cr
P/S: 332.4x
Industry P/S: 2.8x
Created with Highcharts 8.2.2HistoricalGrowthValuationAttractivenessProfitabilityIndustryOutlookPriceStability10
Fundamentals

Sales (Cr) ₹ 7.57
Growth -0.6%
EBITDA -2010.1%
P/S 332.4x
Dividend 0.0%
P/E -17.6x
Book Value ₹ 7.03
PEG Ratio 29.8x
ROE -66.9%
P/B 16.4x
Shareholding Pattern

Institutions
Rambabu Chirumamilla
1.56 %
Iepf
0.14 %
Created with Highcharts 8.2.2Dec19Mar20Jun20Sep20Dec20Mar21Jun21Sep21Mar22Sep22
Promoters
Jasti Property And Equity Holdings Private Limited(Initscapacityassoletrusteeofjastifamilytrust)
60.0 %
Created with Highcharts 8.2.2Dec19Mar20Jun20Sep20Dec20Mar21Jun21Sep21Mar22Sep22
Others
Created with Highcharts 8.2.2Dec19Mar20Jun20Sep20Dec20Mar21Jun21Sep21Mar22Sep22
Increase    Decrease    No change
Company Profile Detailed

Suven Life Sciences was promoted by Mrs. and Mr. Venkat Jasti in 1989, as a Private Limited Company. Later it was converted into a Public Limited Company in January 1995.Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets.
Investors (36)
Followers (7)